John Parkinson is a professor and journalist whose work has appeared in various publications and media outlets. He focuses on a wide range of topics, including healthcare, infectious diseases, public health, and international diplomacy. With his expertise and experience, John provides insightful analysis and reporting on important issues that impact society.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
John Parkinson's coverage focuses on healthcare, pharmaceuticals, government announcements and politics with a particular emphasis on infectious diseases such as COVID-19. This suggests that he would be interested in receiving pitches related to the latest developments in medical research, public health initiatives, vaccine analytics and government decisions impacting healthcare.
Given his focus on citing data and evolving stories within the healthcare sector, John may be particularly receptive to pitches that offer exclusive access to new scientific findings or insights into emerging trends related to infectious diseases.
As there is no specified geographic focus for John's articles, it can be assumed that he covers global issues within the field of healthcare and infectious diseases.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: John Parkinson, Christian John Lillis
Peggy Lillis Foundation CEO Christian Lillis believes patients need a seat at the table so he is advocating for past patients to become ambassadors to be a voice to help shape treatment and also continue to raise awareness about the infection.
By: John Parkinson
At ID Week 2024, in a late-breaking presentation, investigators are reporting it is safe to cut the antibiotic regimen in half without endangering patients for these infections.
By: John Parkinson, Helen Chu
With the approval of newer products, clinicians have tools to prevent the respiratory virus in the most vulnerable population. Helen Chu, MD, MPH, offers some insights on their efficacy and the nuances of the delivery of the 2 immunizations.
By: John Parkinson
The individuals are agricultural workers in Washington state who were in close proximity to and working with infected poultry at an egg farm.
By: John Parkinson
Invivyd’s Chief Scientific Officer Robert Allen, PhD, discusses the company’s pemivibart (Pemgarda) including its administration, how it can be used in concert with vaccines, and how it protects against newer variants.
By: Su H. Wang, Debika Bhattacharya, John Parkinson
Debika Bhattacharya, MD MSc, and Su H. Wang, MD, MPH, FACP, provide important insights on the latest in hepatitis B (HBV) clinical care.
By: John Parkinson
Timothy Ritter, MD, provides his insights on using the live biotherapeutic product and what both patients and clinicians can expect in terms of safety and efficacy.
By: John Parkinson
Carol Pandak, EdD, director of PolioPlus, Rotary International, discusses the significance of this day and efforts that continue around the world to work towards eradication of this disease.
By: John Parkinson
Jose Alexander, MD, offers some insights on the antimicrobial and its activity against various gram-negative pathogens such as pseudomonas, enterobacterales.
By: John Parkinson, Su H. Wang, Debika Bhattacharya
In the second part of their interview, Debika Bhattacharya, MD MSc, and Su H. Wang, MD, MPH, FACP, continue the conversation around the difficulties of getting people into care, and what the new hepatitis B guidelines hope to improve in this area.
(833) 317-6278 
